Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

2024-03-27

财报高管变更

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities. “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer. “The team’s achievements to date, and those on the horizon, are the result of a 10-year record of success in delivering on a promise to develop and commercialize our proprietary AI-Driven DeepView™ System wound healing assessment platform, a technology that we believe can help change the standard of care while delivering value across the healthcare ecosystem. We expect to realize our first commercial product revenue in the second half of this year. Given the pace of our product development and clinical activities in the US and internationally, we believe that we are on the proper path to generate commercial revenue across four separate DeepView™ System platforms covering burn and diabetic foot ulcer (DFU) within the next three years. “We have a well-defined business focus for 2024 based on the evolution of our DeepView™ System from clinical stage to commercialization. We will continue to advance our research and development work under current US Government contracts for our DeepView™ System burn indication and plan to submit regulatory filings for the approval of this indication in the US in the first half of 2025. We are pursuing the commercialization of our DeepView™ System for the assessment of DFU in the US and the UK, and expect to submit regulatory filings for the approval of this indication in the US and UK in 2024. Our recent financing agreements in combination with the multi-year, non-dilutive funding provided by our US Government contracts provides us with a sound financial foundation to pursue these objectives. “ 2023-2024 SELECT BUSINESS HIGHLIGHTS Government Funding In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million. This multi-year, non-dilutive contract includes an initial award of approximately $54.9 million to fund development activities through Q1 2026 for our DeepView™ System for burn to submit a De Novo FDA application, and for government procurement of the device for distribution at various burn centers and emergency rooms across the United States. First Commercial Product Revenue In February 2024, we received UKCA Authorization to commence sales of our DeepView™ System for burn in the UK. We deployed our first burn device in March 2024 and expect to commence generating commercial revenues in the second half of 2024. Regulatory In October 2023, our DeepView SnapShot® wound imaging system received regulatory authorization in the UK and Class 1 medical device classification with the U.S. Food and Drug Administration (FDA). Clinical Trials In January 2023, we provided interim results for our DFU Clinical Study, which will be used in upcoming regulatory submissions in the UK and US. In December 2023, we initiated a pivotal study to validate our DeepView™ System for burn, which is expected to be the final clinical trial before seeking FDA approval. This study is being conducted in burn centers and emergency departments with an enrollment target of 240 subjects in both adult and pediatric patients. Product Development In March 2024, we received a new contract valued at $500,000 from the US Government that provides additional support for the development of the handheld version of our DeepView™ System called DeepView SnapShot® M. This new award brings total support for the DeepView SnapShot® M to more than $6 million. In August 2023, we received ISO 13485 certification for the manufacture and distribution of our DeepView™ System. Corporate Successfully listed on Nasdaq in September 2023, elevating our pro US investors and other stakeholders. Added significant strength and industry depth to our board of directors with the appointments of Deepak Sadagopan, MHCDS, Erich Spangenberg, Dr. J. Michael DiMaio, and to our management team with the additions of Peter M. Carlson and Prof. Paul Chadwick. Enhanced our access to capital by completing an equity financing and entering into a fixed price standby equity purchase agreement with a long-only investor that includes a $12.5 million prepaid advance. 2023 FINANCIAL RESULTS OVERVIEW All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated. Research & Development Revenue Research & Development Revenue1 for Q4 2023 was $5.3 million compared to $6.1 million, primarily due to the implementation of the new BARDA PBS contract, executed in September 2023. For FY 2023, Research & Development revenue was $18.1 million compared to $25.4 million, reflecting a decrease in activity due to the completion of work under the BARDA Burn II contract, partially offset by the commencement of work under the new BARDA PBS contract. Gross Margin Gross margin for Q4 2023 was 46.1% compared to 41.1%. For FY 2023, gross margin rose to 43.6% from 42.7%. The improvement in gross margin for both periods reflected the commencement of work under the BARDA PBS contract, which carries a higher reimbursement rate than the prior BARDA Burn II contract. General & Administrative Expense General & administrative expenses in Q4 2023 were $5.4 million compared to $4.3 million. For FY 2023, general & administrative expenses rose to $20.9 million from $13.5 million. The increase for both periods was the result of increased headcount required to support our organizational growth, and higher costs associated with an increase in non-revenue generating R&D activities. Net Loss Net loss for Q4 2023 was $(3.5) million, or $(0.22) per share, compared to a net loss of $(1.7) million, or $(0.13) per share, for Q4 2022. For FY 2023, the net loss was $(20.9) million, or $(1.48) per share, compared to a net loss of $(2.9) million, or $(0.22) per share, for FY 2022. Net loss for the 2023 period included $8.3 million of non-recurring transaction costs associated with the consummation of the Company’s business combination that resulted in its Nasdaq listing; there were no such costs incurred in 2022. Cash As of December 31, 2023, cash was $4.8 million and the Company had no long-term debt. During the first quarter of 2024, the Company enhanced its financial position, as follows: Received proceeds of $5.0 million via a fixed price prepaid advance and standby equity purchase agreement (SEPA) with a long-only investor with a fixed conversion price of $3.16 as part of a total advance of $12.5 million. The SEPA facility provides for financing of up to $30.0 million in total. Received proceeds of approximately $2.8 million via a committed equity facility that was entered into in December 2023 under which the Company is able to draw an additional $3.0 million prior to utilizing the SEPA facility. ____________________________ 1Research and Development Revenue consisted primarily of funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. 2024 Guidance The Company is reiterating its revenue guidance of approximately $28.0 million for FY 2024. Financial guidance for FY 2024 does not reflect expected contributions from the sale of the DeepView™ System for burn in the UK beginning in the second half of 2024 or any additional material financial contributions that may result from the commercialization of our DeepView™ System. CONFERENCE CALL The Company will host a conference call today at 5:00 pm Eastern Time to discuss these results. Investors interested in participating in the live call can dial: 833-630-1956 – U.S. 412-317-1837 – International A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit . Forward-Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Investors: The Equity Group Devin Sullivan Managing Director dsullivan@equityny.com Conor Rodriguez Analyst crodriguez@equityny.com Media: Russo Partners David Schull Russo Partners (858) 717-2310 david.schull@russopartnersllc.com Spectral AI, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) December 31, December 31, 2023 2022 Assets Current assets: Cash $ 4,790 $ 14,174 Accounts receivable, net 2,346 2,294 Inventory 230 - Unbilled revenue - 618 Deferred offering costs 283 - Prepaid expenses 1,452 331 Other current assets 801 270 Total current assets 9,902 17,687 Non-current assets: Property and equipment, net 12 21 Right-of-use assets 778 1,008 Total Assets $ 10,692 $ 18,716 Commitments and contingencies (Note 8) Liabilities and Stockholders’ Equity (Deficit) Current liabilities: Accounts payable $ 2,683 $ 2,759 Accrued expenses 4,300 2,631 Deferred revenue 2,311 - Lease liabilities, short-term 853 680 Notes payable 436 175 Warrant liabilities 1,818 129 Total current liabilities 12,401 6,374 Lease liabilities, long-term - 346 Total Liabilities 12,401 6,720 Stockholders’ Equity (Deficit) Preferred stock ($0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022 - - Common stock ($0.0001 par value); 80,000,000 shares authorized; 16,294,935 and 13,170,148 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively 2 1 Additional paid-in capital 31,065 23,929 Accumulated other comprehensive income 12 - Accumulated deficit (32,788 ) (11,934 ) Total Stockholders’ Equity (Deficit) (1,709 ) 11,996 Total Liabilities and Stockholders’ Equity (Deficit) $ 10,692 $ 18,716 Spectral AI, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Research and development revenue $ 5,287 $ 6,096 $ 18,056 $ 25,368 Cost of revenue (2,851 ) (3,588 ) (10,176 ) (14,531 ) Gross profit 2,436 2,508 7,880 10,837 Operating costs and expenses: General and administrative 5,365 4,277 20,864 13,484 Total operating costs and expenses 5,365 4,277 20,864 13,484 Operating loss (2,929 ) (1,769 ) (12,984 ) (2,647 ) Other income (expense): Net interest income 44 20 172 21 Change in fair value of warrant liability (669 ) 7 335 57 Foreign exchange transaction loss, net (13 ) 18 (24 ) (237 ) Transaction costs - - (8,342 ) - Total other expense, net (638 ) 45 (7,859 ) (159 ) Loss before income taxes (3.567 ) (1,724 ) (20,843 ) (2,806 ) Income tax provision 21 (15 ) (11 ) (106 ) Net loss $ (3,546 ) $ (1,739 ) $ (20,854 ) $ (2,912 ) Net loss per share of common stock Basic and Diluted $ (0.22 ) $ (0.13 ) $ (1.48 ) $ (0.22 ) Weighted-average common shares outstanding Basic and Diluted 16,097,399 13,164,086 14,087,586 13,136,965 Other comprehensive income: Foreign currency translation adjustments $ 12 $ - $ 12 $ - Total comprehensive loss $ (3,534 ) $ (1,739 ) $ (20,842 ) $ (2,912 ) Spectral AI, Inc. Condensed Consolidated Statements of Cash Flows (in thousands, except share and per share data) Year Ended December 31, 2023 2022 Cash flows from operating activities: Net loss $ (20,854 ) $ (2,912 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 9 11 Stock-based compensation 1,243 1,155 Amortization of right-of-use assets 713 557 Issuance of shares for transaction costs 4,350 - Change in fair value of warrant liabilities (335 ) (57 ) Changes in operating assets and liabilities: Accounts receivable (52 ) (859 ) Inventory (230 ) - Unbilled revenue 618 (547 ) Prepaid expenses (377 ) 615 Other assets (404 ) 40 Accounts payable (935 ) 1,345 Accrued expenses 1,359 51 Deferred revenue 2,311 - Lease liabilities (656 ) (561 ) Net cash used in operating activities (13,240 ) (1,162 ) Cash flows from financing activities: Proceeds from issuance of common stock for Equity Raise 3,351 - Cash received in Business Combination 660 - Payments for notes payable (483 ) (785 ) Stock option exercises 316 - Net cash provided by (used in) financing activities 3,844 (785 ) Effect of exchange rate changes on cash 12 - Net decrease in cash (9,384 ) (1,947 ) Cash, beginning of period 14,174 16,121 Cash, end of period $ 4,790 $ 14,174